The Cooper Companies, Inc. (COO)
The Cooper Companies is a global medical device business that helps people see better through contact lenses and supports women's reproductive health.
Is The Cooper Companies, Inc. a good stock for a UK beginner?
The honest version: The Cooper Companies is a global medical device business that helps people see better through contact lenses and supports women's reproductive health.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Dominance in the growing global contact lens market.
Long-term decline in healthcare spending or regulatory hurdles.
What does The Cooper Companies, Inc. do?
This company operates in two main areas: CooperVision, which makes contact lenses, and CooperSurgical, which provides tools for fertility and women's health. Revenue flows from selling these specialised medical products to eye care professionals and hospitals worldwide. Much comes down to how well they grow sales in these competitive healthcare markets while keeping their manufacturing costs under control.
On our factor screen it looks strongest on value and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 8% over the year
- !High P/E of 61 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- Strong gross margins showing efficient product manufacturing
- Operates in essential healthcare sectors with steady demand
- Lower volatility compared to the broader market
- Income screens low (16/100)
- Heavy reliance on the competitive contact lens market
- Potential for regulatory changes in medical device approvals
- Integration risks from past or future company acquisitions
What do The Cooper Companies, Inc.'s numbers mean?
How much money does The Cooper Companies, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does The Cooper Companies, Inc. pay a dividend?
No - The Cooper Companies, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does The Cooper Companies, Inc. report earnings, and how did recent quarters go?
The Cooper Companies, Inc. is next scheduled to report on about 2026-09-09 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-06-04 | $1.09 | $1.21 | Beat +11% |
| 2026-03-05 | $1.03 | $1.10 | Beat +7% |
| 2025-12-04 | $1.11 | $1.15 | Beat +3% |
| 2025-08-27 | $1.07 | $1.10 | Beat +3% |
| 2025-05-29 | $0.93 | $0.96 | Beat +3% |
| 2025-03-06 | $0.91 | $0.92 | In line |
Across the last 6 quarters here, The Cooper Companies, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for The Cooper Companies, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of The Cooper Companies, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong gross margins showing efficient product manufacturing
- Operates in essential healthcare sectors with steady demand
- Lower volatility compared to the broader market
- Low net profit margin suggests high operating expenses
- Does not pay a dividend to shareholders
- Return on equity is currently quite modest
- Heavy reliance on the competitive contact lens market
- Potential for regulatory changes in medical device approvals
- Integration risks from past or future company acquisitions
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in revenue growth below 5%
- A significant and permanent decline in gross margins
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.